Dianthus Expands Pipeline with DNTH312, Combining Claseprubart and TACI for Autoimmune Diseases — Dianthus Therapeutics, Inc.

Event summary

Dianthus Therapeutics announced DNTH312, a first-in-class bifunctional fusion protein combining claseprubart and TACI for severe autoimmune diseases.
DNTH312 demonstrated comparable in vitro potency and aC1s inhibition to claseprubart with a similar non-human primate (NHP) half-life of 22 days.
The company aims to have DNTH312 ready for Phase 1 trials by the end of 2027.

The big picture

Dianthus Therapeutics is leveraging its expertise in neuromuscular diseases to expand into broader autoimmune indications with DNTH312. This strategic move aims to address larger patient populations and potentially offer deeper responses and broader symptom control. The company's focus on combining validated mechanisms of action positions it competitively in the rapidly evolving landscape of autoimmune disease treatments.

What we're watching

Clinical Efficacy: How DNTH312's dual mechanism of targeting both aC1s and BAFF/APRIL will translate into superior clinical efficacy in severe autoimmune diseases.
Regulatory Timeline: The pace at which Dianthus can advance DNTH312 through Phase 1 trials and secure regulatory approvals.
Market Expansion: Whether DNTH312 can successfully expand Dianthus' leadership position into additional autoimmune diseases beyond neuromuscular conditions.